Internal Medicine, Allergy & Immunology · Allentown, PA
NPI
1124224027
Since 2007
Specialty
Internal Medicine, Allergy & Immunology
Code 207RA0201X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1605 N Cedar Crest Blvd Ste 605
Allentown, PA, 18104
Phone (610) 820-9000
Groups this clinician bills Medicare through
Medicare paid, 2024
$161K
7,205 services
Medicare patients, 2024
221
Average age 70
Drug cost, 2024
$1.2M
1,240 prescriptions
Company payments, 2025
$830
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert M Zemble was code 95004 (test - miscellaneous), 1,802 times for 34 patients. In total Robert M Zemble billed 7,205 services in 38 codes, and Medicare paid $161K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-09-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95004 Test - Miscellaneous | Office | 1,802 | 34 | $2.43 | $4,387 |
| 95165 Treatment - Miscellaneous | Office | 1,180 | 57 | $9.33 | $11K |
| 95117 Treatment - Miscellaneous | Office | 588 | 56 | $7.67 | $4,508 |
| 94375 Pulmonary Function Testing | Office | 155 | 104 | $25.17 | $3,902 |
| 95115 Treatment - Miscellaneous | Office | 146 | 26 | $6.32 | $922 |
| 95012 Pulmonary | Office | 137 | 97 | $12.18 | $1,668 |
| 99214 Office E&M - Established | Office | 111 | 73 | $83.00 | $9,213 |
| 99213 Office E&M - Established | Office | 48 | 41 | $53.49 | $2,567 |
| 96160 E&M - Miscellaneous | Office | 41 | 37 | $1.74 | $71.54 |
| 99204 Office E&M - New | Office | 28 | 28 | $112.17 | $3,141 |
| G0008 Administration of influenza virus vaccine | Office | 26 | 26 | $30.77 | $800 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 23 | 20 | $11.95 | $275 |
| 94060 Pulmonary Function Testing | Office | 23 | 23 | $26.34 | $606 |
| 90662 Vaccine Product | Office | 20 | 20 | $81.33 | $1,627 |
| 99205 Office E&M - New | Office | 15 | 15 | $155.51 | $2,333 |
By year: 2022 $191K for 9,377 services; 2023 $126K for 6,387 services; 2024 $161K for 7,205 services.
Medicare prescription drug claims, 2024
In 2024, the drug Robert M Zemble prescribed most often to Medicare patients was Fluticasone Propionate, with 161 prescriptions and refills. In total Robert M Zemble wrote 1,240 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Fluticasone Propionate Generic | 161 | 282 | 51 | $2,942 |
| Montelukast Sodium Generic | 132 | 357 | 44 | $1,356 |
| Azelastine Hcl Generic | 131 | 225 | 53 | $5,044 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 55 | 101 | 12 | $63K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 48 | 58 | 23 | $1,703 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 45 | 95 | 13 | $9,960 |
| Dupixent Pen Dupilumab | 38 | 38 | Under 11 | $140K |
| Epinephrine Generic | 34 | 34 | 26 | $6,543 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 33 | 47 | 18 | $8,001 |
| Breo Ellipta Fluticasone/Vilanterol | 33 | 43 | Under 11 | $16K |
| Dulera Mometasone/Formoterol | 32 | 51 | 13 | $17K |
| Levocetirizine Dihydrochloride Generic | 31 | 85 | 11 | $433 |
| Mometasone Furoate Generic | 29 | 51 | 11 | $4,087 |
| Olopatadine Hcl Generic | 28 | 58 | 12 | $3,365 |
| Xolair Omalizumab | 28 | 28 | Under 11 | $39K |
Brand drugs: 493 claims; generic drugs: 747 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert M Zemble $830 ($830 in general payments such as food, travel and fees) from 8 companies. The largest payer was CSL Behring with $238.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.